NO20053566L - Vitamin D3 laktonderivater - Google Patents

Vitamin D3 laktonderivater

Info

Publication number
NO20053566L
NO20053566L NO20053566A NO20053566A NO20053566L NO 20053566 L NO20053566 L NO 20053566L NO 20053566 A NO20053566 A NO 20053566A NO 20053566 A NO20053566 A NO 20053566A NO 20053566 L NO20053566 L NO 20053566L
Authority
NO
Norway
Prior art keywords
optionally hydroxylated
hydrogen
vitamin
lactone derivatives
hydroxylated
Prior art date
Application number
NO20053566A
Other languages
English (en)
Other versions
NO332287B1 (no
Inventor
Hiroshi Saitoh
Seiichi Ishizuka
Kazuya Takenouchi
Miyuki Anzai
Kazuhisa Okada
Daishiro Miura
Hiroaki Takayama
Atsushi Kittaka
Nozomi Saito
Toshie Fujishima
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of NO20053566L publication Critical patent/NO20053566L/no
Publication of NO332287B1 publication Critical patent/NO332287B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

En forbindelse representert ved den følgende formel (1) eller et farmasøytisk akseptabelt solvat av forbindelsen. De er effektive i behandlingen av Pagets bensykdom eller hyperkalemi. R1 angir hydrogen, eventuelt hydroksylert C1-C6 alkyl, eller eventuelt hydroksylert hydrogen, eller eventuelt hydroksylert C1-C6alkoksy, R2a og R2b representerer begge hydrogen, eventuelt hydroksylert C1-C10alkyl, eventuelt hydroksylert C6-C10aryl eller eventuelt hydroksylert C7-C12aralkyl eller R2a og R2b samlet representerer etylen, forutsatt at forbindelsene hvor R1 er hydrogen eller metyl og R2a og R2b er hydrogen er utelukket.
NO20053566A 2003-01-30 2005-07-21 Vitamin D3 Laktonderivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater omfattende slike samt slike forbindelser for behandling av sykdom NO332287B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003021650 2003-01-30
JP2003339658 2003-09-30
PCT/JP2004/000815 WO2004067525A1 (ja) 2003-01-30 2004-01-29 ビタミンｄ３ラクトン誘導体

Publications (2)

Publication Number Publication Date
NO20053566L true NO20053566L (no) 2005-08-24
NO332287B1 NO332287B1 (no) 2012-08-13

Family

ID=32828907

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053566A NO332287B1 (no) 2003-01-30 2005-07-21 Vitamin D3 Laktonderivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater omfattende slike samt slike forbindelser for behandling av sykdom

Country Status (11)

Country Link
US (1) US9073885B2 (no)
EP (1) EP1589009B1 (no)
JP (1) JP4361528B2 (no)
KR (1) KR101092277B1 (no)
CN (1) CN1771239B (no)
AU (1) AU2004207719B9 (no)
BR (1) BRPI0407104A (no)
CA (1) CA2514614C (no)
NO (1) NO332287B1 (no)
NZ (1) NZ541158A (no)
WO (1) WO2004067525A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053165A1 (ja) 2008-11-04 2010-05-14 帝人ファーマ株式会社 ビタミンｄ３ラクタム誘導体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346241A1 (de) 1983-03-31 1984-10-04 Siemens AG, 1000 Berlin und 8000 München Parallelverknuepfungsschaltung mit verkuerztem uebertragsdurchlauf
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
ATE201397T1 (de) 1994-06-07 2001-06-15 Teijin Ltd Vitamin d3 derivate und ein verfahren zu ihrer herstellung
US5877168A (en) * 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
DE69606680T2 (de) * 1995-10-30 2000-08-17 Hoffmann La Roche 1-Alpha, 26-dihydroxy-D-homo-vitamin D3
JPH11116551A (ja) * 1996-09-05 1999-04-27 Teijin Ltd ビタミンｄ３誘導体およびその製造法
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
DE69810273T2 (de) 1997-05-02 2003-08-28 Teijin Ltd Vitamin d 3? derivate und verfahren zur herstellung derselben
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
US6531460B1 (en) * 1998-10-23 2003-03-11 Teijin Limited Vitamin D, derivatives and remedies for inflammatory respiratory diseases containing the same
JP2002069003A (ja) * 2000-08-23 2002-03-08 Teijin Ltd ビタミンｄ誘導体を含有する骨吸収抑制剤
TW200303206A (en) * 2002-02-20 2003-09-01 Teijin Ltd Vitamin D3 derivatives and remedies using the same
JP4381248B2 (ja) 2004-07-23 2009-12-09 Ｆｄｋ株式会社 電極端子の固定構造およびその固定方法
AU316086S (en) * 2007-07-09 2007-09-12 Onesteel Wire Pty Ltd Fence post driver
JP4407756B2 (ja) 2008-02-11 2010-02-03 株式会社デンソー ヒートポンプ式加熱装置

Also Published As

Publication number Publication date
NZ541158A (en) 2008-03-28
EP1589009A1 (en) 2005-10-26
KR101092277B1 (ko) 2011-12-13
WO2004067525A1 (ja) 2004-08-12
AU2004207719A1 (en) 2004-08-12
EP1589009A4 (en) 2008-05-07
AU2004207719B9 (en) 2009-10-01
JPWO2004067525A1 (ja) 2006-05-18
NO332287B1 (no) 2012-08-13
CN1771239B (zh) 2010-06-09
AU2004207719A8 (en) 2004-08-12
CN1771239A (zh) 2006-05-10
EP1589009B1 (en) 2014-10-08
US20060148768A1 (en) 2006-07-06
AU2004207719B2 (en) 2009-08-06
CA2514614A1 (en) 2004-08-12
CA2514614C (en) 2011-09-13
KR20050097953A (ko) 2005-10-10
US9073885B2 (en) 2015-07-07
BRPI0407104A (pt) 2006-01-24
JP4361528B2 (ja) 2009-11-11

Similar Documents

Publication Publication Date Title
ATE377420T1 (de) Phenylalkansäure- und phenyloxyalkansäure- derivate als hppar aktivatore
NO20060219L (no) Forbindelser
DK1089998T3 (da) Epothilon-derivater samt deres syntese og anvendelse
DK1485359T3 (da) Natriumkanalblokkere
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
NO20053133L (no) Kjemiske forbindelser.
BR0309447A (pt) Composto, agente, processos para a preparação dos mesmos, e para o combate do crescimento de plantas indesejadas, e, uso do composto
AU2002317829A1 (en) Photostable organic sunscreen compounds with antioxidant properties and compositions obtained therefrom
WO2002018324A3 (en) Immunoregulatory compounds, derivatives thereof and their use
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
DE60319080D1 (de) Phenyloxyalkansäure-derivate als hppar aktivatore
EP1634874A4 (en) imidazolidine
IL136911A0 (en) Heterocyclic topoisomerase poisons
NO20053566L (no) Vitamin D3 laktonderivater
HK1080282A1 (en) Improved formulations containing substituted imidazole derivatives
NZ517315A (en) New derivatives of A-500359
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
HK1077070A1 (en) Oligosaccharide derivative
NO921282L (no) Benzotiazolderivater og deres anvendelse
NO20020291L (no) Terapeutiske og profylaktiske midler for neoplasmer
WO2004094396A3 (en) Dihydrothiazine prodrugs of thiazolium agents
EP1659117A4 (en) 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE
EP1632228A4 (en) MEDICINAL COMPOSITION CONTAINING TRIAZOLE COMPOUND
MXPA04001552A (es) Derivados de n-fenil 2-hidroxi-2-metil-3,3,3-trifluropropanamida sustituida que elevan la actividad de la piruvato deshidrogenasa.
MX2008002753A (es) Derivados de piridazinona utilizados para el tratamiento de dolor.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TEIJIN LTD, JP

MM1K Lapsed by not paying the annual fees